|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Biologic MateR clinical performance test for ADA and TCZ Efficacy prediction - Biologic MateR clinical performance test for ADA and TCZ Efficacy prediction
Start Date04 Nov 2014 |
Sponsor / Collaborator- |
Estudio piloto, doble ciego, aleatorizado, controlado con placebo, de dosis repetida, para la evaluación de la seguridad y la eficacia antiviral de HPH116 en pacientes infectados por VIH-1 que no hayan recibido tratamiento previoA pilot, double-blinded, randomized, placebo-controlled, repeated dose, assessing HPH116 antiviral safety and efficacy in naïve HIV-1 infected patients. - PoC
Start Date05 Sep 2007 |
Sponsor / Collaborator- |
100 Clinical Results associated with CD8 x HIV p7 x CD4
100 Translational Medicine associated with CD8 x HIV p7 x CD4
0 Patents (Medical) associated with CD8 x HIV p7 x CD4